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Background. Shortening the interval between antituberculosis treatment onset and initiation of antiretroviral
therapy (ART) reduces mortality in severely immunocompromised human immunodeﬁciency virus (HIV)–infected
patients with tuberculosis. A better understanding of causes and determinants of death may lead to new strategies to
further enhance survival.
Methods. We assessed mortality rates, causes of death, and factors of mortality in Cambodian HIV-infected
adults with CD4 count ≤200 cells/µL and tuberculosis, randomized to initiate ART either 2 weeks (early ART) or
8 weeks (late ART) after tuberculosis treatment onset in the CAMELIA clinical trial.
Results. Six hundred sixty-one patients enrolled contributed to 1366.1 person-years of follow-up; 149 (22.5%) died.
There were 8.3 deaths per 100 person-years (95% conﬁdence interval [CI], 6.4–10.7) in the early-ART group and 13.8
deaths per 100 person-years (95% CI, 11.2–16.9) in the late-ART group (P = .002). Tuberculosis was the primary cause
of death (28%), followed by other HIV-associated conditions (19%). Factors independently associated with mortality in
the ﬁrst 26 weeks were the age, body mass index, hemoglobin, interrupted or ineffective tuberculosis treatment before
identiﬁcation of drug resistance, disseminated tuberculosis, and nontuberculous mycobacterial disease. After 50 weeks
in the trial, the most frequent causes of death were non-HIV related or tuberculosis related, including drug toxicity;
factors associated with mortality were late ART, loss to follow-up, and absence of cotrimoxazole prophylaxis.
Conclusions. Despite ART introduction, mortality remained high, with tuberculosis as the leading cause of death.
Reducing tuberculosis-related mortality remains a challenge in resource-limited settings and requires innovative strat-
egies.
Clinical Trials Registration. NCT00226434.
Keywords. tuberculosis; HIV; mortality; cause of death; adult.
Despite advances in tuberculosis diagnosis and access to
treatment for human immunodeﬁciency virus (HIV)
infection, tuberculosis remains a major cause of death
in HIV-infected patients [1, 2]. In 2012, it was estimated
that 1.0–1.2 million new tuberculosis cases and 0.32
million tuberculosis-related deaths occurred in HIV-
infected persons, accounting for 13% of the global
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tuberculosis burden and 25% of tuberculosis mortality [1]. Sever-
al randomized clinical trials showed the positive impact upon
mortality of shortening the delay between tuberculosis treatment
onset and initiation of antiretroviral therapy (ART) [3–7]. The
level of immunosuppression [3, 4] and the location or severity
of tuberculosis disease [6] have been reported to impact the sur-
vival beneﬁt gained from earlier ART initiation [3–7].
Notably, in general, data are scarce on tuberculosis-related
factors associated with mortality in HIV-infected adults treated
for tuberculosis. Observational and autopsy studies showed
that tuberculosis itself constitutes the principal cause of death
[8–10], but other HIV-related opportunistic infections are fre-
quently reported as the etiology of death. Thus, a deeper under-
standing of the causes and factors associated with death is
needed to develop strategies aiming to further reduce mortality
in HIV-infected patients treated for tuberculosis.
Here, we assessed mortality rates, causes, and risk factors of
death in HIV-infected patients enrolled in the CAMELIA
(Cambodian Early vs Late Introduction of Antiretroviral Ther-
apy) randomized clinical trial. We speciﬁcally analyzed (1) early
deaths before 26 weeks of follow-up (W26), where mortality is
thought to be mainly linked to the severity of initial presenta-
tion and expected to be related to HIV and tuberculosis; and (2)
late deaths after 50 weeks of follow-up (W50), at a time when
most patients would be expected to have been cured from
their tuberculosis and to have recovered a level of protective im-
munity in general [11, 12].
METHODS
Study Design and Patients
CAMELIA was a randomized, open-label clinical trial designed
to determine whether early initiation of ART 2 weeks after the
onset of tuberculosis treatment, as compared with 8 weeks,
would reduce mortality in HIV-infected adults with tuberculo-
sis and advanced immunodeﬁciency. The inclusion procedures
and study design have been described elsewhere [5]. In brief,
after signed informed consent, treatment-naive adults with
CD4 count ≤200 cells/µL and smear-positive tuberculosis
were recruited in 5 Cambodian hospitals from January 2006
to May 2009 and randomized to initiate ART with stavudine,
lamivudine, and efavirenz either 2 weeks (early ART) or 8
weeks (late ART) after the initiation of tuberculosis treatment.
Tuberculosis treatment consisted of a standard daily regimen of
isoniazid, rifampin, ethambutol, and pyrazinamide during the
ﬁrst 2 months followed by isoniazid and rifampin during the
following 4 months. Mycobacterial cultures were systematically
performed and drugs were available at study sites to adapt treat-
ment in the case of drug resistance or nontuberculous mycobac-
teria. Patients received cotrimoxazole prophylaxis. Fluconazole
was also given when the CD4 count was <100 cells/µL.
Patients had follow-up visits at 2, 4, 8, 10, 14, 18, 22, 26, 34,
42, 50, 58, and 78 weeks after tuberculosis treatment onset, and
every 6 months thereafter until the end of the study, which was
50 weeks after the last patient was enrolled. ART could be mod-
iﬁed in case of toxicities, and systematic switch from stavudine
to zidovudine was encouraged after W50 to minimize the risk of
mitochondrial toxicities. In accordance with Cambodian na-
tional guidelines [13], cotrimoxazole and ﬂuconazole prophy-
laxes were discontinued once CD4 cell count was maintained
at >200 cells/µL and >100 cells/µL, respectively, for >6 months.
All treatments were self-administered, and patients received ad-
herence counseling. The trial was approved by the Cambodian
National Ethics Committee for Health Research, and the ethical
review boards of the Immune Disease Institute at Harvard Med-
ical School and Médecins Sans Frontières.
Deﬁnitions and Outcomes
Paradoxical tuberculosis-associated immune reconstitution in-
ﬂammatory syndrome (TB-IRIS) was deﬁned as worsening or
emergence of signs or symptoms of tuberculosis (eg, fever,
cough, shortness of breath, lymph node, or exacerbation of dis-
ease at other extrapulmonary sites) occurring after the initiation
of ART, excluding differential diagnoses (poor adherence, drug
toxicity, and other diseases). Validation procedures have been
described elsewhere [14]. For this analysis, we deﬁned inade-
quate tuberculosis therapy as either interruption of effective
antituberculosis drugs for >3 consecutive days, whatever the
reason, or ineffective tuberculosis drugs received before the
drug susceptibility testing results for >3 consecutive days.
Tuberculosis outcome at W50 was deﬁned as (1) cured or treat-
ment completed: patients who completed tuberculosis treat-
ment and had resolution of symptoms with or without
negative sputum smear or culture in the last month of treat-
ment, with no subsequent recurrence; (2) ongoing tuberculosis
treatment: patients who were still on tuberculosis treatment for
any reason (initial treatment interruption or failure, drug resis-
tance, tuberculosis recurrence); or (3) other: patients known to
be alive and either not cured or having completed treatment or
not receiving ongoing tuberculosis treatment. Loss to follow-up
was deﬁned as absence of known vital status at the end of the
study. At W50, patients were classiﬁed as having interrupted
follow-up if they had not attended protocol visits for 12
weeks or more but were known to be alive beyond this point.
Assessment of Causes of Death
Site investigators primarily assessed the cause of death. When
death occurred at home, they were requested to perform an in-
terview of family members to attempt to assess the cause of
death. Medical records of all patients who died were subse-
quently reviewed by 2 investigators not involved in day-to-day
clinical management to validate the assigned cause of death.
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Causes of death were classiﬁed into one of the following catego-
ries, as suggested previously [8]: tuberculosis, HIV-associated
conditions (excluding tuberculosis), tuberculosis or HIV-
associated conditions equally likely when it could equally be re-
lated to both infections, and nontuberculosis/HIV-associated
conditions. The latter was divided into drug toxicity and
other nontuberculosis/HIV-associated causes of death. TB-
IRIS was classiﬁed as an HIV-associated condition.
Statistical Methods
Early mortality was deﬁned as deaths occurring before W26;
follow-up was thus censored at W26, or at the date of death,
date of withdrawal, or date of last visit for the patients lost to
follow-up, whichever occurred ﬁrst. To identify factors associat-
ed with early mortality, the Cox proportional hazard model was
used. Those factors investigated included known risk factors of
HIV and tuberculosis mortality such as CD4 cell count, body
mass index (BMI), hemoglobin count, chest radiographic fea-
tures, and mycobacterial disease pattern at inclusion, and
time-dependent variables such as occurrence of TB-IRIS and
inadequate tuberculosis therapy.
Late mortality was deﬁned as death occurring after W50; only
patients with a follow-up >50 weeks were considered in this
analysis. The Cox model was used to identify factors associated
with late mortality. Due to informative missing values in several
factors investigated, multiple imputations were performed [15].
A sensitivity analysis was performed, considering only patients
with all data available at W50.
For all factors included in the Cox models, the proportional
hazard assumption was validated using a test on Schoenfeld re-
siduals. All factors associated with the outcome with a P value
<.20 in univariate analysis were entered in the multivariate
model. A backward selection procedure was applied to identify
factors independently and signiﬁcantly associated with the out-
come. A P value <.05 was considered signiﬁcant. All analyses
were performed using the Stata 12 software (StataCorp, College
Station, Texas).
RESULTS
Characteristics of Patients
Six hundred sixty-one patients were enrolled in the trial
(Figure 1). Their baseline characteristics have been described
elsewhere and did not differ between the early-ART and late-
ART groups [5]. In summary, patients had advanced immuno-
deﬁciency (median CD4 count, 25 cells/µL), low BMI (median,
16.7 kg/m2) (Table 1), and high levels of viremia with median
Figure 1. Enrollment and follow-up. Abbreviations: ART, antiretroviral therapy; W50, week 50.
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plasma HIV RNA level of 5.64 (interquartile range [IQR], 5.24–
6.01) log10 copies/mL. Tuberculosis was culture-conﬁrmed in
577 (87.3%) patients, and 16 (2.4%) patients had nontubercu-
lous mycobacteria disease identiﬁed with culture. Patients
were followed for a median time of 25 (IQR, 14–36) months
with a total of 1366.1 person-years of follow-up accrued during
the study.
At W50, 540 patients were still alive and in the study
(Figure 1). Among them, 520 (96.3%) were on ART, 436
(80.7%) and 245 (45.4%) were still receiving cotrimoxazole
and ﬂuconazole prophylaxis, respectively, 23 (4.3%) were still
on tuberculosis treatment, and 13 (2.4%) had interrupted fol-
low-up (Table 1). Compared to baseline, median weight gain
was 9 kg (IQR, 5–12 kg) and median CD4 cell count gain was
164 (IQR, 107–224) cells/µL. Overall, 496 of 513 (96.7%) pa-
tients on ART with available measurement had undetectable
HIV RNA (<2.4 log10 copies/mL).
Mortality Rates: Sites of Death
One hundred forty-nine patients died during the study: 87
(58.4%) before W26, 22 (14.8%) between W26 and W50, and
40 (26.8%) after W50. Overall, the mortality rate was 10.9
deaths per 100 person-years (95% conﬁdence interval [CI],
9.3–12.8). There were 8.3 deaths per 100 person-years (95%
CI, 6.4–10.7) in the early-ART group and 13.8 deaths per 100
person-years (95% CI, 11.2–16.9) in the late-ART group
(P = .002). Mortality decreased from 55.9 deaths per 100 per-
son-years (95% CI, 33.1–94.4) in the ﬁrst 2 weeks to 4.9 deaths
per 100 persons-years (95% CI, 3.6–6.7) after W50 (P < .001;
Table 2). After W50, mortality remained higher in the late-
ART group compared with the early-ART group with rates of
7.0 (95% CI, 4.8–10.3) and 3.0 (95% CI, 1.8–5.2) deaths per
100 person-years, respectively (P = .01). Death occurred during
hospitalization in 86 patients (57.7%) and at home in 63 pa-
tients (42.3%).
Causes of Death
Tuberculosis was the most common cause of death (28.2%),
followed by HIV-associated conditions (18.8%) (Table 3).
There were no signiﬁcant differences in the distribution of cat-
egories of causes of death between the early-ART and late-ART
groups (P = .32). Tuberculosis was the most frequent cause of
early deaths (37.9%) and also accounted for 17.5% of late
deaths. Before W26, the tuberculosis-speciﬁc mortality rate
was 6.6 (95% CI, 3.5–12.2) deaths per 100 person-years in
the early-ART group and 16.2 (95% CI, 10.9–24.2) deaths
per 100 person-years in the late-ART group (P = .013). HIV-
associated conditions accounted for 18.4% of deaths before
W26 and for 7.5% after W50. Six deaths directly attributed
to TB-IRIS occurred in the early-ART group. Other non-
tuberculosis or HIV-related identiﬁed causes of death (gastro-
intestinal and nontoxic hepatic disorders, neoplasia, suicide,
road trafﬁc accident, and stroke) were predominant after
W50 (27.5%), followed by drug toxicity (22.5%), including 8
of 9 cases related to lactic acidosis. Individual data for all
patients who died after W50 are presented in Supplementary
Data.
Risk Factors of Mortality
Factors independently associated with a higher risk of early
death included age ≥40 years, BMI ≤16 kg/m2, hemoglobin
Table 1. Characteristics of Enrolled Patients at 2 Time Points of
Speciﬁc Interest: Inclusion and After 50 Weeks of Follow-up
Characteristic
No. (%) of Patients at
Inclusion (n = 661)
No. (%) of Patients at
Week 50 (n = 540)
Sex, male 425 (64.3) 355 (65.7)
Age, y, median
(IQR)
35 (30–41) 35 (30–41)
BMI, kg/m2, median
(IQR)
16.7 (15.2–18.4) 20.4 (18.8–22.2)a
CD4 count, cells/µL
Median (IQR) 25 (10–56) 199 (142–274)b
≤50 475 (71.9) 5 (0.9)
51–200 186 (28.1) 264 (48.9)
201–350 0 (0) 179 (33.1)
>350 0 (0) 71 (13.2)
Missing 0 (0) 21 (3.9)
HIV RNA <2.4 log10
copies/mL
0 (0) 501 (96.2)c
Hemoglobin, g/dL,
median (IQR)
8.7 (7.1–10.3) 13.4 (12.2–14.5)c
Treatment group
Early ART 332 (50.2) 281 (52.0)
Late ART 329 (49.8) 259 (48.0)
Temporarily lost to
follow-up at week
50
NA 13 (2.4)
ART regimen
Stavudine-
lamivudine-
efavirenz
0 (0) 441 (81.7)
Other ART
regimens
0 (0) 79 (14.6)
No ART 661 (100.0) 20 (3.7)
Cotrimoxazole
prophylaxis
644 (97.4) 436 (80.7)
Fluconazole
prophylaxis
560 (84.7) 245 (45.4)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV, human
immunodeficiency virus; IQR, interquartile range; NA, not applicable.
a Available for 523 patients.
b Available for 519 patients.
c Available for 518 patients.
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<70 g/L, disseminated tuberculosis or nontuberculousmycobacterial
disease at enrollment, and inadequate tuberculosis therapy (Table 4).
Factors assessed at W50 that were independently associated
with late death included the late-ART group, interruption in
follow-up, and absence of cotrimoxazole prophylaxis (Table 5).
When those patients who had interrupted follow-up before
W50 were excluded from the analysis, factors independently as-
sociated with mortality were the late-ART group (hazard ratio
[HR], 2.34; 95% CI, 1.13–4.86), BMI ≤17 kg/m2 (HR, 4.29; 95%
CI, 1.53–12.01) and absence of cotrimoxazole prophylaxis (HR,
2.22; 95% CI, 1.01–4.76).
DISCUSSION
This study provides in-depth analysis of mortality in naive
HIV-infected adults treated for tuberculosis in the CAMELIA
trial. Introduction of ART led to a signiﬁcant and quick reduc-
tion of mortality in adults with tuberculosis and advanced HIV-
associated immunodeﬁciency with early ART initiation, leading
to a 34% global reduction in mortality compared with late
ART initiation [5]. However, despite prompt tuberculosis treat-
ment initiation and ART initiation, mortality remained high
during the ﬁrst 6 months following tuberculosis diagnosis,
and tuberculosis was the leading cause of these deaths. Notably,
late mortality among the patients who were still alive at W50
was more than double in those who received late ART or who
discontinued cotrimoxazole prophylaxis.
CAMELIA patients presented at a late stage in their HIV dis-
ease, with profound immunosuppression, which contributed to
the high global mortality initially observed in the study [16, 17].
Mortality before ART initiation was >50 deaths per 100 person-
years, consistent with ﬁndings from other studies conducted in
patients with advanced immunodeﬁciency [18]. Despite the
>10-fold decrease of mortality between enrollment and after
W50, and the faster reduction of mortality in patients initiating
ART 2 weeks after tuberculosis treatment, mortality remained
roughly >20 deaths per 100 patient-years during the ﬁrst
6 months on ART. Surprisingly, CD4 cell count was not associ-
ated with mortality in multivariate analysis. In a study with 72%
of patients presenting with a CD4 count <50 cells/µL, mortality
may have been mainly driven by poor general condition, reﬂect-
ed by low BMI and anemia, both contributing to increased risk
of early death. Notably, global mortality remained relatively
high after W50, reaching 4.9 deaths per 100 person-years as
compared with 1.0 per 100 person-years in a cohort of Thai pa-
tients started on ART at higher CD4 cell counts [19].
Tuberculosis was the main cause of death here, consistent
with data from another Southeast Asian cohort study of severely
immunocompromised patients that showed that 27% of deaths
occurring over 6 months were tuberculosis-related, with an ad-
ditional 23% potentially related to tuberculosis-associated con-
ditions [8]. Another randomized clinical trial attributed 32% of
deaths as being related to tuberculosis over 1 year of follow-up
[4]. In our study, although most tuberculosis-associated deaths
occurred before week 26, tuberculosis also accounted for 17.5%
of the late deaths, mostly due to tuberculosis recurrence. This
conﬁrmed the high mortality rates observed in HIV-infected
patients with recurrent tuberculosis [20].
Tuberculosis-speciﬁc factors that contributed to increased mor-
tality were related to both interruption or inadequacy of treatment
and the pattern of disease presentation. Inadequate therapy due to
use of a standard tuberculosis treatment in patients who were later
found to have drug-resistant tuberculosis or treatment interrup-
tion was associated with a 2-fold increased risk of death. Study
arm–independent drug-induced hepatitis and rashes were fre-
quent in the study and contributed to treatment interruptions.
Furthermore, disseminated tuberculosis, known to be associated
with increased mortality [21–23], was associated with a 2-fold in-
creased risk of death. However, extrapulmonary tuberculosis
alone or noncavitary or normal chest radiographs were not asso-
ciated with higher mortality [22].
Residual mortality due to tuberculosis could be reduced by
faster access to appropriate treatment through faster diagnosis.
Early detection of multidrug resistant tuberculosis is now
Table 2. Distribution of Deaths by Period of Time and Treatment Group
Period
Early ART Late ART Total
No.
Mortality Rate (95% CI)
per 100 PY No.
Mortality Rate (95% CI)
per 100 PY No.
Mortality Rate (95% CI)
per 100 PY
Overall 59 8.3 (6.4–10.7) 90 13.8 (11.2–16.9) 149 10.9 (9.3–12.8)
Inclusion–W2 7 55.6 (26.5–116.7) 7 56.1 (26.8–117.7) 14 55.9 (33.1–94.4)
W2–W8 10 27.3 (14.7–50.8) 15 41.7 (25.1–69.2) 25 34.5 (23.3–51.0)
W8–W26 20 19.4 (12.5–30.1) 28 28.1 (19.4–40.7) 48 23.7 (17.8–13.2)
W26–W50 9 6.8 (3.6–13.1) 13 10.6 (6.2–18.3) 22 8.7 (5.7–3.2)
>W50 13 3.0 (1.8–5.2) 27 7.0 (4.8–10.3) 40 4.9 (3.6–6.7)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; PY, person-year; W, week.
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possible through automated nucleic acid ampliﬁcation tests
(NAATs) [24]or other molecular assays [25] that were not avail-
able during the CAMELIA trial. Rapid diagnosis of disseminat-
ed tuberculosis by detection of bacteremia on whole-blood
NAATs [26], however, may have limited impact, as mortality
remains high with the existing standard tuberculosis regimens
[23]. Therefore, intensiﬁcation of tuberculosis treatment with
higher doses of rifampicin [27] or innovative regimens [28]
should be considered, especially for patients who exhibit severe
immunosuppression.
Table 3. Causes of Death by Period of Time and Treatment Group
Cause of Death
Inclusion–W26 W26–W50 After W50
Total (n = 149),
No. (%) [Occurring
in Hospital]
[n = 86], No.
Early ART
(n = 37),
Late ART
(n = 50),
Early ART
(n = 9),
Late ART
(n = 13),
Early ART
(n = 13),
Late ART
(n = 27),
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Tuberculosis 10 (27.0) 23 (46.0) 0 (0) 2 (15.4) 3 (23.1) 4 (14.8) 42 (28.2) [24]
Tuberculosis 10 15 0 1 1 0 27 [14]
MDR tuberculosis 0 8 0 0 0 1 9 [7]
Tuberculosis recurrence 0 0 0 1 2 3 6 [3]
HIV-associated conditions 10 (27.0) 10 (20.0) 3 (33.3) 2 (15.4) 0 (0) 3 (11.1) 28 (18.8) [19]
Diarrhea 1 4 0 1 0 1 7 [4]
Nontuberculous mycobacterial
disease
3 1 1 1 0 0 6 [5]
TB-IRIS 4 0 2 0 0 0 6 [4]
Progressive multifocal
leukoencephalopathy
1 2 0 0 0 0 3 [2]
Cryptococcosis 1 1 0 0 0 0 2 [2]
Encephalitis 0 1 0 0 0 1 2 [0]
Bacterial pneumonia 0 1 0 0 0 0 1 [1]
Pneumocystis jirovecii
pneumonia
0 0 0 0 0 1 1 [1]
Tuberculosis or HIV-associated
condition equally likely
7 (18.9) 7 (14.0) 3 (33.3) 2 (15.4) 3 (23.1) 1 (3.7) 23 (15.4) [12]
Respiratory distress 3 2 1 1 2 1 10 [4]
Cachexia 4 3 0 0 1 0 8 [5]
Coma 0 2 1 1 0 0 4 [3]
Meningitis 0 0 1 0 0 0 1 [0]
Drug toxicity 1 (2.7) 3 (6.0) 1 (11.1) 3 (23.1) 3 (23.1) 6 (22.2) 17 (11.4) [15]
Lactic acidosis 0 0 1 1 3 5 10 [8]
Hepatotoxicity 0 2 0 0 0 0 2 [2]
Toxic epidermal necrolysis 0 1 0 1 0 0 2 [2]
Drug hypersensitivity 0 0 0 0 0 1 1 [1]
Electrolyte disordersa 0 0 0 1 0 0 1 [1]
Pancytopenia 1 0 0 0 0 0 1 [1]
Other nontuberculosis/HIV-
associated conditions
7 (18.9) 5 (10.0) 1 (11.1) 2 (15.4) 3 (23.1) 8 (29.6) 26 (17.4) [15]
Gastrointestinal disorders 5 1 0 1 0 2 9 [6]
Nontoxic hepatic disorder 1 4 0 0 2 1 8 [7]
Neoplasia 0 0 0 0 0 3 3 [3]
Suicide 1 0 0 1 1 0 3 [1]
Road traffic accident 0 0 0 0 0 2 2 [0]
Stroke 0 0 1 0 0 0 1 [1]
Unknown 2 (5.4) 2 (4.0) 1 (1.1) 2 (15.4) 1 (7.7) 5 (18.5) 13 (8.7) [2]
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; MDR, multidrug resistant; TB-IRIS, paradoxical tuberculosis-associated immune
reconstitution inflammatory syndrome; W, week.
a Profound hyponatremia and hypokalemia in the context of unremitting vomiting due to drug intolerance.
440 • CID 2014:59 (1 August) • HIV/AIDS
 by guest on Septem
ber 29, 2014
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Table 4. Risk Factors of Early Deaths (Cox Model)
Risk Factor
No. of
Patients
Deaths, No.
(%)
Crude HR on Univariate
Analysis (95% CI)
P
Value
Adjusted HR on Multivariate
Analysis (95% CI)
P
Value
Treatment group .13
Early ART 332 37 (11.1) 1
Late ART 329 50 (15.2) 1.38 (.91–2.11)
Sex .38
Male 425 52 (12.2) 1
Female 236 35 (14.8) 1.21 (.79–1.86)
Age at inclusion, y .04 .003
≤29 151 13 (8.6) 1 1
30–39 292 36 (12.3) 1.49 (.79–2.80) 1.71 (.90–3.24)
≥40 218 38 (17.4) 2.13 (1.13–3.99) 2.83 (1.49–5.36)
BMI at inclusion, kg/m2 .003 .02
≤16.0 243 47 (19.3) 2.72 (1.44–5.12) 2.32 (1.21–4.44)
16.1–17.0 128 14 (10.9) 1.45 (.67–3.13) 1.34 (.62–2.92)
17.1–18.5 135 14 (10.4) 1.36 (.63–2.94) 1.25 (.57–2.71)
>18.5 155 12 (7.7) 1 1
CD4 at inclusion, cells/µL .005
≤25 335 58 (17.3) 3.67 (1.33–10.12)
26–50 140 15 (10.7) 2.16 (.72–6.51)
51–100 107 10 (9.3) 1.88 (.59–6.01)
101–200 79 4 (5.1) 1
Hemoglobin at inclusion, g/dL .001 .01
≤7.0 165 37 (22.4) 3.45 (1.86–6.38) 2.48 (1.31–4.72)
7.1–10.0 301 36 (12.0) 1.72 (.93–3.18) 1.47 (.79–2.75)
>10.0 195 14 (7.2) 1 1
Mycobacterial disease pattern <.001 <.001
Pulmonary 442 42 (9.5) 1 1
Extrapulmonary 82 10 (12.2) 1.31 (.66–2.62) 1.21 (.60–2.41)
Disseminateda 121 30 (24.8) 2.86 (1.79–4.57) 2.47 (1.53–4.00)
Nontuberculous mycobacteria 16 5 (31.2) 3.93 (1.55–9.93) 3.46 (1.36–8.86)
Drug-resistant tuberculosis at
inclusion
.23
No 541 69 (12.7) 1
Yes 107 14 (13.1) 1.01 (.57–1.79)
Multidrug resistanceb 13 4 (30.8) 2.77 (1.01–7.59)
Inadequate tuberculosis therapyc,
d
.02 .03
No 1 1
Yes 2.25 (1.22–4.17) 1.96 (1.06–3.63)
Chest radiograph at inclusion .15
Normal 127 18 (14.2) 1
Cavitary pattern 436 58 (13.3) 0.95 (.56–1.62)
Abnormal without cavity 97 10 (13.3) 0.72 (.30–1.57)
Missing 1 1 (100.0) 23.10 (3.01–177.54)
Occurrence of TB-IRISd .61
No 1
Yes 0.84 (.41–1.71)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; HR, hazard ratio; TB-IRIS, paradoxical tuberculosis-associated immune
reconstitution inflammatory syndrome.
a Disseminated tuberculosis was defined as pulmonary tuberculosis associated with any type of extrapulmonary tuberculosis.
b Multidrug resistance was defined as resistance to both isoniazid and rifampicin.
c Interruption of effective antituberculosis drugs for >3 consecutive days, whatever the reason, or ineffective tuberculosis drugs received before the drug-
susceptibility testing results for >3 consecutive days.
d Time-dependent factor.
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Table 5. Risk Factors of Late Deaths (Cox Model With Multiple Imputations of Missing Values)
Risk Factor
Patients,
No.
Deaths No.
(%)
Crude HR on Univariate
Analysis (95% CI)
P
Value
Adjusted HR on Multivariate
Analysisa (95% CI)
P
Value
Treatment group .01 .023
Early ART 281 13 (4.6) 1 1
Late ART 259 27 (10.4) 2.31 (1.19–4.48) 2.28 (1.15–4.50)
Sex .28
Male 355 23 (6.5) 1
Female 185 17 (9.2) 1.41 (.76–2.65)
Age at inclusion, y .77
≤29 129 11 (8.5) 1
30–39 240 16 (6.7) 0.76 (.35–1.63)
≥40 171 13 (7.6) 0.88 (.39–1.96)
BMI at W50b, kg/m2 .12
≤17.0 30 5 (16.7) 3.46 (1.27–9.40)
17.0–18.4 76 4 (5.3) 1.00 (.33–3.07)
18.5–20.0 122 9 (7.4) 1.33 (.58–3.05)
>20.0 295 15 (5.1) 1
CD4 at W50b, cells/µL .31
≤100 49 4 (8.2) 2.16 (.43–10.94)
101–200 220 10 (4.5) 1.19 (.27–5.29)
201–350 179 17 (9.5) 2.29 (.58–9.06)
>350 71 2 (2.8) 1
Plasma HIV RNA at W50b .67
Undetectable 498 31 (6.2) 1
≥2.4 log10 copies/mL 20 2 (10.0) 1.37 (.33–5.67)
Hemoglobin at W50b, g/dL .33
>10.0 495 30 (6.1) 1.80 (.55–5.85)
≤10.0 23 3 (13.0) 1
Tuberculosis outcome at W50 .005
Cured or treatment completed 512 33 (6.4) 1
Ongoing treatment 19 3 (15.8) 3.03 (.93–9.92)
Not cured and no treatment 9 4 (44.4) 7.04 (2.49–19.91)
Chest radiograph at W50b .72
Normal 410 23 (5.6) 1
Abnormal 102 8 (7.8) 1.18 (.46–3.02)
History of TB-IRIS .13
No 405 34 (8.4) 1
Yes 135 6 (4.4) 0.53 (.22–1.27)
ART at W50 <.001
Stavudine-lamivudine-
efavirenz
441 28 (6.3) 1
Other combination 79 5 (6.3) 1.00 (.39–2.59)
None 20 7 (35.0) 7.22 (3.14–16.58)
Temporarily lost to follow-up at
W50
<.001 .01
No 527 33 (6.3) 1 1
Yes 13 7 (53.8) 11.53 (5.09–26.13) 4.34 (1.53–12.33)
Fluconazole prophylaxis at W50 .24
No 295 27 (9.1) 1.78 (.88–3.59)
Yes (never interrupted) 213 11 (5.2) 1
Yes (previously interrupted) 32 2 (6.2) 1.25 (.28–5.62)
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In our study, TB-IRIS accounted for 6 deaths, exclusively in
the early-ART group. As expected, early ART initiation led to a
higher incidence of TB-IRIS in these severely immunocompro-
mised patients, especially those presenting with disseminated or
extrapulmonary tuberculosis [14]. However, the global mortal-
ity was lower in this study arm, and the occurrence of TB-IRIS
events was not associated with overall mortality.
The survival advantage associated with early ART continued
to increase after W50, long after the study intervention. Such a
ﬁnding was unexpected in a population of patients with a high
tuberculosis cure rate, and similarly favorable immunovirolog-
ical outcomes in both study groups, after roughly 1 year on
ART. This difference in mortality raises the possibility that
the study intervention led to differences in functional immune
recovery with equal absolute lymphocyte counts (Haridas V,
Pean P, Jasenosky LD, et al, manuscript in preparation).
Lactic acidosis was an important cause of death after W50.
Surprisingly, the occurrence of symptomatic hyperlactatemia
on stavudine-containing ART, which was standard of care in
Cambodia and used in the trial, was high in CAMELIA [5], as
compared with rates observed previously [29, 30]. This high in-
cidence was unexpected in patients with low BMIs [31], which
in turn may have contributed to the poor outcomes of lactic ac-
idosis in the trial [32]. One explanation could be the rapid
weight gain that was observed during the ﬁrst year on ART.
Of importance, the interruption of cotrimoxazole prophylax-
is before W50 was associated with an approximate 3-fold in-
crease in the risk of death. Most patients with data available
at W50 who died later had CD4 counts >200 cells/µL. The
use of cotrimoxazole prophylaxis impacts overall mortality,
probably due to its role in the prevention of invasive bacterial
disease [33, 34], an effect observed up to 72 weeks after ART ini-
tiation, even in patients with a CD4 count >200 cells/µL [35].
Despite the small number of obvious infectious causes of
death after W50 in the trial, this suggests that the optimal
time for discontinuation of cotrimoxazole prophylaxis should
be reconsidered in HIV-infected patients with tuberculosis
[36, 37].
A major limitation of our study is the lack of autopsies since
discrepancies between clinical assessment of cause of death and
pathological ﬁndings have been reported to be frequent [9].
However, this may have led us to underestimate tuberculosis
or other opportunistic infections as causes of death. In CAMEL-
IA, both a limited access to sophisticated diagnostic procedures
and a high proportion of deaths occurring at home complicated
the assessment of cause of death. Another potential limitation
of our study is the severely immunosuppressed nature of the
population included in CAMELIA, which may restrict the gen-
eralization of our results to all HIV-infected patients with tuber-
culosis in different settings.
Three trials have gathered strong evidence in favor of early
introduction of ART after tuberculosis treatment onset in se-
verely immunocompromised patients [3–5]. Of these, CAMEL-
IA has the longest duration of follow-up. This enabled us to
show that the beneﬁt of early ART initiation was prolonged.
To improve further long-term outcomes, we propose that the
question of the appropriate time for cotrimoxazole prophylaxis
interruption should be reconsidered. Tuberculosis played a
major role in mortality in this patient series, especially during
the ﬁrst 6 months following diagnosis. Thus, optimized
case management should include early ART initiation and
opportunistic infection prophylaxis, appropriate management
of TB-IRIS and toxicities, and support of adherence to avoid
treatment interruption, but also possibly intensiﬁcation of
tuberculosis initial treatment. Together with intensiﬁed clini-
cal and microbiological case ﬁnding strategies, such innovative
approaches may help reduce mortality linked to tuberculosis
and HIV.
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Table 5 continued.
Risk Factor
Patients,
No.
Deaths No.
(%)
Crude HR on Univariate
Analysis (95% CI)
P
Value
Adjusted HR on Multivariate
Analysisa (95% CI)
P
Value
Cotrimoxazole at W50 .001 .02
No 104 16 (15.4) 3.03 (1.61–5.70) 2.62 (1.19–5.77)
Yes 436 24 (5.5) 1 1
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; TB-IRIS, paradoxical
tuberculosis-associated immune reconstitution inflammatory syndrome; W50, week 50.
a Multivariate model is stratified on viral load at enrollment for which proportional hazard ratio assumption was not verified.
b Factors with imputed values.
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